The DOI matches its Crossref record; 428 of the 428 references it cites were found in a registry or an index.
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
Open accessAbstract
Diabetes mellitus type 2 is a world-wide growing health problem affecting more than 150 million people at the beginning of the new millennium. It is believed that this number will double in the next 25 yr. The pathophysiological hallmarks of type 2 diabetes mellitus consist of insulin resistance, pancreatic β-cell dysfunction, and increased endogenous glucose production. To reduce the marked increase of cardiovascular mortality of type 2 diabetic subjects, optimal treatment aims at normalization of body weight, glycemia, blood pressure, and lipidemia. This review focuses on the pathophysiology and molecular pathogenesis of insulin resistance and on the capability of antihyperglycemic pharmacological agents to treat insulin resistance, i.e., α-glucosidase inhibitors, biguanides, thiazolidinediones, sulfonylureas, and insulin. Finally, a rational treatment approach is proposed based on the dynamic pathophysiological abnormalities of this highly heterogeneous and progressive disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–428 of 428
Peripheral and hepatic insulin sensitivity in subjects with impaired glucose tolerance
Berrish, T. S., Hetherington, C., Alberti, K. G. M. M., & Walker, M. (1995) · Diabetologia · doi:10.1007/bf00401842 · Cited by 26
Morel, Y., Golay, A., Perneger, T., Lehmann, T. N., Vadas, L., Pasik, C., & Reaven, G. M. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00120.x · Cited by 25
Kolterman, O. G., & Olefsky, J. M. (1984) · PubMed · Cited by 24
Teupe, B., & Bergis, K. (1991) · PubMed · Cited by 24
Hermann, L. S., Kjellström, T., & Nilsson‐Ehle, P. (1991) · PubMed · Cited by 22
Fibrinogen, fibrinolysis and diabetes mellitus: a comment
Vague, P., & Juhan-Vague, I. (1997) · Diabetologia · doi:10.1007/s001250050743 · Cited by 22
Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulphonylurea therapy
Leslie, P. J., Jung, R. T., Isles, T. E., & Baty, J. D. (1987) · Clinical Science · doi:10.1042/cs0730041 · Cited by 21
The impact of sulfonylureas on hepatic glucose metabolism in type II diabetics
Kolterman, O. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030203 · Cited by 20
Cellular loci of sulfonylurea actions.
Lebovitz, H. E. (1984) · PubMed · Cited by 19
Hepatic sensitivity to insulin: Effects of sulfonylurea drugs
Prato, S. D., de Kreutzenberg, S. V., Riccio, A., & Tiengo, A. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90415-t · Cited by 18
Effects of the sulfonylureas on muscle glucose homeostasis
Smith, R. J. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90334-a · Cited by 18
Boyd, K., Rogers, C., Boreham, C. A. G., Andrews, W. J., & Hadden, D. R. (1992) · PubMed · Cited by 16
Ahr, H. J., Krause, H., Siefert, H. M., Steinke, W., & Weber, H. J. (1989) · PubMed · Cited by 16
Pontiroli, A. E., Alberetto, M., Bertoletti, A., Baio, G., & Pozza, G. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2007-1014925 · Cited by 16
Tessari, P., Biolo, G., Bruttomesso, D., Inchiostro, S., Panebianco, G., Vedovato, M., Fongher, C., & Tiengo, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989455 · Cited by 15
Pedersen, O. B., Nielsen, O. H., Bak, J. F., Hjøllund, E., & Beck‐Nielsen, H. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90414-s · Cited by 13
In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin dependent) diabetes.
Nielsen, O. H., Schmitz, O., Andersen, P. H., Pedersen, O. B., & Beck‐Nielsen, H. (1988) · PubMed · Cited by 13
Sulfonylurea Therapy Fails to Diminish Insulin Resistance in Type I-Diabetic Subjects
Keller, U., Müller, R., & Berger, W. (1986) · Hormone and Metabolic Research · doi:10.1055/s-2007-1012384 · Cited by 12
Glucose‐lowering effect of BTS 67 582
Page, T., & Bailey, C. J. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701537 · Cited by 12
Maloff, B. L., Drake, L., Riedy, D., & Lockwood, D. H. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90408-4 · Cited by 11
Sulfonylurea effects on target tissues for insulin.
McCaleb, M. L., Maloff, B. L., Nowak, S., et al. (1984) · PubMed · Cited by 10
Gliclazide and insulin action in human muscle
Bak, J. F., & Pedersen, O. B. (1991) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(91)90009-3 · Cited by 10
Glyburide in non-insulin-dependent diabetes: an update.
Kolterman, O. G. (1992) · PubMed · Cited by 10
Effects of glyburide on In Vivo insulin-mediated glucose disposal
Simonson, D. C. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90335-b · Cited by 9
[Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics].
Leblanc, H., Thote, A., Châtellier, G., et al. (1990) · PubMed · Cited by 5
Schulz, B., Ratzmann, K. P., Heinke, P., & Besch, W. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1210280 · Cited by 4
Genome-Wide Scan for CAG/CTG Repeat Expansions in Pimas with Early Onset of Type 2 Diabetes Mellitus
DiStefano, J. K., Bogardus, C., & Procházka, M. (1999) · Molecular Genetics and Metabolism · doi:10.1006/mgme.1998.2775 · Cited by 2
UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years
UK Prospective Diabetes Study (UKPDS) Group, Matthews, D. R., Cull, C. A., Stratton, I. M., Holman, R. R., & Turner, R. C. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199804)15:4
Cited by
Association between insulin resistance and the development of cardiovascular disease
Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0762-4 · Cited by 2,280
Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., & Birnbaum, M. J. (2001) · Science · doi:10.1126/science.292.5522.1728 · Cited by 1,836
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Transcriptional Regulation of Metabolism
Desvergne, B., Michalik, L., & Wahli, W. (2006) · Physiological Reviews · doi:10.1152/physrev.00025.2005 · Cited by 892
Er, L.-K., Wu, S., Chou, H.-H., Hsu, L.-A., Teng, M.-S., Sun, Y.-C., & Ko, Y.-L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149731 · Cited by 708
Metadata
- Authors
- Matthaei, S., Stumvoll, M., Kellerer, M., & Häring, H.-U.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2000-12-01
- Volume
- 21
- Issue
- 6
- Pages
- 585-618
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2011419421
- Cited by
- 377
- References
- 428
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.